Access Advance Extends Founding Licensee Incentives for Video Distribution Patent Pool Through September 30, 2025
4.8.2025 18:51:00 CEST | Business Wire | Press Release
Access Advance LLC today announced an extension of its Founding Licensee incentive program for the Video Distribution Patent (VDP) Pool through September 30, 2025. The incentive program, which originally concluded on June 30, 2025, offers significant savings in royalty payments for video streaming providers seeking comprehensive video codec licensing coverage across HEVC, VVC, VP9, and AV1 technologies. The VDP Pool Licensors have approved this extension to give potential Licensees additional time to qualify for the Founding Licensee benefits.
Founding Licensees will receive a 25% reduction in standard royalty rates and a complete waiver of back royalties through 2024. The extension gives potential licensees an additional period to qualify for these benefits by signing a license. The extension responds to continued market interest from video distributors evaluating the VDP Pool's one-stop licensing solution following the recent announcement of major industry participants including ByteDance, Kuaishou, NTT Docomo, and Tencent joining as Licensees of the VDP Pool.
"The strong initial response to our VDP Pool launch demonstrates the market's need for simplified video codec licensing," said Peter Moller, CEO of Access Advance. "By extending these Founding Licensee benefits, we're providing additional time for video streaming providers to evaluate how the VDP Pool can simplify and optimize their patent licensing while delivering meaningful savings in royalty payments. Some companies have asked us to extend the qualifying date for Founding Licensee incentives to December 31, 2025, but the Licensors have not yet made a decision about that request."
Interested companies are encouraged to promptly contact Access Advance at licensing@accessadvance.com and lock in the Founding Licensee incentives before the current September 30, 2025 deadline.
About Access Advance: Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers.
Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 27,500 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit: www.accessadvance.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250804048040/en/
Contacts
Media Contact:
Meredith Hollander
Director, Strategic Communications
Access Advance LLC
Email: press@accessadvance.com
Website: www.accessadvance.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.accessadva
nce.com&esheet=54302531&newsitemid=20250804048040&lan=en-US&anchor=www.accessadv
ance.com&index=2&md5=b7ae5b491d1751ef497665db0e6df3f8
Licensing Inquiries:
Email: licensing@accessadvance.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom